Legha S S, Slavik M, Carter S K
Cancer. 1976 Oct;38(4):1535-41. doi: 10.1002/1097-0142(197610)38:4<1535::aid-cncr2820380415>3.0.co;2-m.
Nafoxidine is a nonsteroidal antiestrogen available as an investigational agent from the Investigational Drug Branch of the National Cancer Institute. It has been used effectively in the treatment of breast cancer patients. A cumulative response rate of 31% is reported for a total of 200 patients treated with this drug. Most patients have been treated with a dose of 60 mg three times a day. Side effects include dryness of skin, photosensitivity reactions and, less commonly, partial hair loss. There is a strong correlation of response to nafoxidine with the presence of estrogen receptor in the tumor and also with the response to previous hormonal treatment. Nafoxidine is a useful addition to the list of hormonal treatments in the therapy of breast cancer.
萘福昔定是一种非甾体类抗雌激素药物，可从美国国立癌症研究所的研究药物部门作为研究用药获取。它已被有效地用于治疗乳腺癌患者。据报道，总共200例接受该药物治疗的患者累积缓解率为31%。大多数患者接受的剂量是每日三次，每次60毫克。副作用包括皮肤干燥、光敏反应，较少见的是部分脱发。对萘福昔定的反应与肿瘤中雌激素受体的存在以及既往激素治疗的反应密切相关。萘福昔定是乳腺癌治疗中激素治疗药物清单中的一个有用补充。
